Published on 9 May 2016
Manuel
Llobet, chief executive of Allergy Therapeutics plc (LON:AGY) says the
latest data from its Phase II trial of its PQBirch204 treatment for hay
fever caused by birch pollen is “exciting for our company”.
Allergy released the results from the latest clinical study, which assessed the response from 371 patients.
The phase II trial revealed a statistically significant dose-response relationship from the groups receiving the medication, with Llobet noting the company has received “very strong top –line data”.
It means the company is still on track to start the Phase III study in early 2017, and Llobet
says the data is “another step towards our
clinical goal to get Polinex Quattro Birch registered in Europe as soon
as possible”.
http://www.4-traders.com/ALLERGY-THERAPEUTICS-PLC-4004878/
Welcome to Allergy Therapeutics, a European-based pharmaceutical company dedicated to continued allergy prevention.
http://www.4-traders.com/ALLERGY-THERAPEUTICS-PLC-4004878/
Allergy Therapeutics
www.allergytherapeutics.com/
CEO of Allergy Therapeutics (LON:AGY) comments on positive phase II data#pharmaceutical #pharma #allergysolution pic.twitter.com/ddqE0U1EvU
— Five Minute Pitch TV (@fiveminutepitch) May 10, 2016
Immunomic Therapeutics is MD Tech Council 2016 Life Science Co. MoCo firm game-changer in allergy vaccines! @MCEDC https://t.co/qo4jjOlGSb
— Judy Stephenson (@MCSmallBizNav) June 3, 2016
Allergy Therapeutics director on novel dust mite allergy treatment https://t.co/ownC0VuNnw https://t.co/yX8BAmfrUr
— Michael Schmitt (@michaelbloggs) June 2, 2016
Global Allergy Diagnostics And Therapeutics Market Size, Share, Analysis, Outlook and… https://t.co/U0vlXbFrki
— BizPR (@bizpressrelease) May 30, 2016
#Gamblingnews Allergy Therapeutics plc (AGY) Stock Rating Reaffirmed by Panmure Gordon https://t.co/ou6PL0ShKf
— All Gambling News (@pokerporn) May 30, 2016
No comments:
Post a Comment